Alps (ALPS)
Combines biotechnology research, medical services, and wellness solutions around predictive, preventive, and precision medicine.
Something off on this page? Send us feedback.
Generates revenue chiefly from aesthetic, medical, and wellness services while developing a biotechnology and precision-medicine platform. The listed Cayman parent owns a Malaysia-rooted operating group.
Runs biotechnology research and development alongside medical services and wellness solutions, with predictive, preventive, and precision medicine as the strategic focus. It combines service delivery with research and development on a bench-to-bedside platform. Current revenue has chiefly come from aesthetic treatments, cosmetic procedures, general healthcare, and wellness services, especially through Alps Wellness Centre and Alps Medical Centre.
Based in Kuala Lumpur, the Malaysia-rooted group operates through a Cayman-listed parent created in the Globalink transaction. Its bench-to-bedside ambition depends on services funding operations while research candidates advance; the prospectus said no product candidates were approved for commercial sale.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $607.5K · Total debt $559.3K · Total assets $7.0M · Shareholders' equity −$2.9M
- Revenue
- $0
- Operating income
- −$450.8K
- Net income
- −$828.4K
No dividends on record.
| Institutions7 holders · as of Mar 31, 2026 | 0.30% | 504.0K shares | |
| Insiders10 holders · as of Apr 20, 2026 | 117.25% | 195.11M shares | |
| Adds to | 117.55% |
166.40M company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 117.55%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Dr. THAM Seng KongInsider | 46.36% | 77.14M | 13Dfiled Nov 12, 2025 ↗ |
Seng Kong ThamInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 46.36% | 77.14M | Form 4filed Mar 20, 2026 ↗ |
Lim Kuang SiaInsider | 10.32% | 17.17M | 13Gfiled Nov 3, 2025 ↗ |
Crystal Propel Sdn. Bhd.Insider | 9.47% | 15.75M | 13Gfiled Nov 3, 2025 ↗ |
Yoke Ling ChewInsiderdirector | 4.14% | 6.88M | Form 4filed Mar 24, 2026 ↗ |
| See all 17 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- Fulgent Genetics
Genetic and laboratory testing with physician interpretation
- Prenetics Global
Consumer longevity and science-backed daily nutrition
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alps | $0.3915 | +3.05% | $63.2M | — | — | 18.8 | — |
| Fulgent Genetics | $20.03 | +2.22% | $569.1M | — | — | 1.8 | +4.4% |
| Prenetics Global | $25.94 | +0.50% | $442.9M | — | — | 3.1 | +162.9% |
| Median | — | — | 2.4 | +83.7% |